JNJ: Surgical Robot, Dividend Hike, and Talc Settlement

Johnson & Johnson (JNJ) has had a strong year, with shares up 28% versus the S&P 500's 8% gain. The company recently received FDA clearance for its Ottava robotic-assisted surgery system, which will compete in the growing surgical robotics market. Additionally, JNJ raised its dividend for the 64th consecutive year, maintaining its status as a Dividend King.

On the financial front, JNJ reported second-quarter net sales of $25.3 billion, up 6.6% year over year, and is on track to generate over $100 billion in annual revenue for only the second time in biopharmaceutical history.

Perhaps most significantly, JNJ reached a proposed settlement with law firms representing most plaintiffs in talc-related lawsuits, agreeing to pay up to $5.5 billion. The settlement is contingent on at least 95% of claimants participating, with initial payments starting in 2027.

This development could finally resolve the long-standing legal overhang that has weighed on the stock. JNJ generated $22.6 billion in free cash flow over the trailing 12 months, making the settlement manageable.

Beyond these headlines, JNJ continues to innovate with new drug approvals like Icotyde for plaque psoriasis and Imaavy for generalized myasthenia gravis, as well as a promising anticoagulant, milvexian, developed with Bristol Myers Squibb.

The talc settlement is the most important catalyst for JNJ investors. For years, the lawsuits created uncertainty and reputational damage. A resolution would remove a major overhang, potentially leading to multiple expansion as the market re-rates the stock.

The Ottava surgical robot opens a new growth avenue in the underpenetrated robotic surgery market, which could become a significant revenue driver. JNJ's medtech segment will benefit from this innovation.

JNJ's dividend hike reinforces its appeal to income investors. With 64 consecutive years of increases, the stock offers reliable income growth, supported by strong free cash flow.

The company's diversified business model—spanning pharmaceuticals, medtech, and consumer health (now spun off)—provides resilience against headwinds like drug pricing negotiations and biosimilar competition.

Finally, the pipeline of new drugs (Icotyde, Imaavy, milvexian) positions JNJ for sustained growth. Milvexian, in particular, could be a blockbuster anticoagulant, developed with BMY and CELG (now part of BMS).